Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perflexane SCHEMBL6860804 | 1.00 | LMNA (0.57) | LMNATHRBCA2CA1MMP1 | |
| Perflenapent SCHEMBL8195291 | 1.00 | LMNA (0.57) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1924377 | 0.94 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| Perflexane SCHEMBL20769778 | 0.94 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL3743142 | 0.94 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL984715 | 0.94 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1707474 | 0.94 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| Perflexane SCHEMBL3671912 | 0.94 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1779065 | 0.94 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL771546 | 0.94 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080029-A1 | Methods for delivering compounds into a cell | IMARX PHARMACEUTICAL CORPORATION (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080029-A1 | Methods for delivering compounds into a cell | ABCB4, NPC1L1, IAPP | LMNA 420/4885THRB 3441/4885CA2 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.